

Innovative Immunotherapy in Advanced *Basal Cell Carcinoma*

Evolving Science, Key Clinical Evidence, and Implications for Multidisciplinary Management



Wednesday, August 11, 2021



5:30 PM - 6:30 PM PT



Zoom Meeting

Meeting ID: 860 0853 4398

Passcode: 902415



Karl D. Lewis, MD

Professor with Tenure

Division of Medical Oncology, Department of Medicine

University of Colorado Anschutz Medical Campus

Director, Cutaneous Oncology Clinical Research Program

University of Colorado Cancer Center

Aurora, Colorado

Activity Description

Basal cell carcinoma (BCC) is a commonly occurring skin malignancy that is easily treatable with surgery and/or radiation when detected at an early stage. However, advanced disease is typically associated with a poor prognosis and is often more challenging to treat, even with targeted agents (because of adverse events and the potential for acquired resistance). Advances in the understanding of BCC pathogenesis first suggested a role for immunotherapy via PD-1 blockade, and follow-up research has led to regulatory approval of immune treatment, including in patients who have progressed on or are unable to receive hedgehog pathway inhibitors.

This "Seminars and Tumor Board" live program will provide an expert-led tour of the evidence that supports incorporating immunotherapy into existing treatment protocols for advanced BCC. Scientific lectures will be linked with practical, case-centered sessions designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards in order to clearly illustrate how oncologists can adapt their current practice and offer the power of immune-based treatment to patients with BCC. Request a meeting at your institution today!

Target Audience

This activity has been designed to meet the educational needs of oncologists, dermatologists, nurses, pharmacists, and other clinicians involved in the management of basal cell carcinoma.

Educational Objectives

Upon completion of this accredited CE activity, participants should be better able to:

- Describe the mechanistic rationale and potential clinical role of immune checkpoint inhibitors in the treatment of basal cell carcinoma
- Summarize clinical evidence on the use of checkpoint inhibitors in patients with locally advanced or metastatic basal cell carcinoma, including in patients progressing on prior therapy
- Integrate immunotherapy into the management of patients with basal cell carcinoma in consultation with the wider management team
- Recognize the spectrum of immune-related adverse events associated with the use of immunotherapy in the basal cell carcinoma setting

Accreditation, Credit, and Support

Physician Continuing Medical Education

Medical Learning Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points and 1.0 Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development

Medical Learning Institute, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.4 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. (MLI) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: 0468-9999-21-017-L01-P

Type of Activity: Knowledge